Understanding the real-life effectiveness of RSV products is of major public health importance. The PROMISE Consortium has developed two protocols for observational studies to assess preventive product (monoclonal antibody or vaccine) effectiveness: one using the test-negative design, the other, for cohort studies using electronic databases. These outputs are intended as generic protocols which can be adapted to specific settings and modified to account for local data availability.
The Innovative Medicines Initiative is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). It is working to improve health by speeding up the development of the next generation of medicines, particularly in areas where there is an unmet medical or social need. It works by facilitating collaboration between the key players involved in health research, including universities, research centres, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. IMI is the world’s biggest public-private partnership (PPP) in the life sciences.
© 2023 | IMI-Promise
